CN109464451B - Medicine for treating neurasthenia and preparation method thereof - Google Patents
Medicine for treating neurasthenia and preparation method thereof Download PDFInfo
- Publication number
- CN109464451B CN109464451B CN201910035030.9A CN201910035030A CN109464451B CN 109464451 B CN109464451 B CN 109464451B CN 201910035030 A CN201910035030 A CN 201910035030A CN 109464451 B CN109464451 B CN 109464451B
- Authority
- CN
- China
- Prior art keywords
- medicine
- treating neurasthenia
- quetiapine
- trimetazidine
- loxoprofen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Abstract
The invention relates to the technical field of neurology, in particular to a medicine for treating neurasthenia, which comprises the following components in percentage by mass: trimetazidine: 2-4%, midecamycin: 1-5% of theophylline: 30-40% and taurine: 15-17% and ketotifen: 2-6% and catechin: 23-25% and nicotinamide: 3-5% of oleanolic acid: 1-3%, quetiapine: 1.5-2.5%, loxoprofen: 2.5 to 11.5 percent. The invention also discloses a preparation method of the medicine, which comprises the following steps: the method comprises the following steps: preparing materials, step two: drying and grinding into powder, and step three: and (5) crushing treatment, namely step four: preparing an ethanol solution, and carrying out step five: concentrating and drying, and step six: and (5) extracting the medicine. The traditional Chinese medicine composition can effectively improve the body function and improve the immunity, has obvious curative effect on treating neurasthenia, has no toxic or side effect on human bodies, can relieve anxiety and cognitive deficiency symptoms, and has the effects of clearing heat, removing internal heat, regulating qi and dredging collaterals.
Description
Technical Field
The invention relates to the technical field of neurology, in particular to a medicine for treating neurasthenia and a preparation method thereof.
Background
Neurasthenia is a broad term and currently generally includes a portion of depression, anxiety disorders, tension headaches, insomnia, dyspepsia, and the like. Neurasthenia refers to the phenomenon of easy excitation and mental fatigue due to long-term tension and stress, often accompanied by emotional distress, irritability, sleep disorder, muscular tension pain, and the like, which cannot be attributed to brain, body diseases and other mental diseases, and has mild and severe symptoms, fluctuation related to psychosocial factors and long-lasting course of disease.
In terms of treatment, modern medicine advocates that psychotherapy is adopted on one hand, chemical medicine is adopted for treatment on the other hand, the chemical medicine only has symptomatic treatment effect on neurasthenia, and most of the anxiolytic agents such as tranquilizers are used at present and have the effects of improving mood of patients with neurasthenia, relaxing muscles, tranquilizing and hypnotizing and the like, so that the anxiolytic agents are effective on psychological and physiological symptoms of the patients, but the anxiolytic agents have good effects only in short-term use, have poor curative effects and are easy to cause drug dependence after long-term use, and the neurasthenia is protracted in disease period, and the short-term chemical medicine is used for symptomatic treatment, so that the problem cannot be solved fundamentally.
Therefore, it is necessary to provide a medicine for treating neurasthenia and a preparation method thereof to solve the above problems.
Disclosure of Invention
Technical problem to be solved
In order to solve the above problems in the prior art, the present invention provides a medicament for treating neurasthenia and a preparation method thereof.
(II) technical scheme
In order to achieve the purpose, the invention adopts the main technical scheme that:
a medicine for treating neurasthenia in neurology comprises the following components (in percentage by mass): trimetazidine: 2-4%, midecamycin: 1-5% of theophylline: 30-40% and taurine: 15-17% and ketotifen: 2-6% and catechin: 23-25% and nicotinamide: 3-5% of oleanolic acid: 1-3%, quetiapine: 1.5-2.5%, loxoprofen: 2.5 to 11.5 percent.
According to the invention, the medicament for treating neurasthenia is an oral dosage form, and the oral dosage form is a tablet.
According to the invention, the dosage of the medicament for treating neurasthenia for adults is 2.6-2.8 mg/kg/day, wherein kg refers to the weight unit of a patient.
According to the invention, the composition comprises the following components (in percentage by mass): trimetazidine: 2.5%, midecamycin: 4.5%, theometin: 31% and taurine: 16%, ketotifen: 2.5%, catechin: 24.5%, nicotinamide: 3.3% and oleanolic acid: 2.7%, quetiapine: 1.6%, loxoprofen: 11.4 percent.
According to the invention, the composition comprises the following components (in percentage by mass): trimetazidine: 3%, midecamycin: 2%, dimenhydrinate: 35% and taurine: 16%, ketotifen: 4%, catechin: 24%, nicotinamide: 4%, oleanolic acid: 2%, quetiapine: 2%, loxoprofen: 8 percent.
According to the invention, the composition comprises the following components (in percentage by mass): trimetazidine: 3.5%, midecamycin: 1.5%, and theimetone: 39.5%, taurine: 15.5%, ketotifen: 5%, catechin: 24%, nicotinamide: 4%, oleanolic acid: 2%, quetiapine: 2.3%, loxoprofen: 2.7 percent.
The invention also provides a method for preparing the medicine.
A preparation method of a medicine for treating neurasthenia comprises the following steps:
the method comprises the following steps: preparing materials: taking trimetazidine, midecamycin, theetarnerone, taurine, ketotifen, catechin, nicotinamide, oleanolic acid, quetiapine and loxoprofen according to the weight parts for later use respectively;
step two: drying and grinding into powder: putting trimetazidine, midecamycin, tea-leaf maiden, taurine, ketotifen, catechin, nicotinamide, oleanolic acid, quetiapine and loxoprofen into an oven for drying at 60-80 ℃, then carrying out a cooling process, and then putting into a dispensing tank for grinding into fine powder;
step three: and (3) crushing treatment: putting the prepared fine powder into an ultrafine pulverizer, and pulverizing into mixed powder consisting of micron-sized particles with volume average particle size of 0.3-12 microns and nano-sized particles with volume average particle size smaller than 0.3 microns for later use;
step four: preparing an ethanol solution: adding ethanol with the mass 2-4 times of that of the mixed powder, and stirring and dissolving to obtain an ethanol solution;
step five: concentrating and drying: standing the ethanol solution at the temperature of 6-8 ℃ for 20-23 hours, slowly percolating at the speed of 2-3 ml per minute by a percolation method, collecting percolate, concentrating and drying for later use;
step six: extracting the medicine: and adding deionized water into the concentrated and dried mixed powder, stirring and dissolving uniformly, heating and concentrating to be pasty, standing for 0.6-0.9 hour, extracting and preparing into tablets to obtain the medicine for treating neurasthenia.
According to the invention, the crushing time in the third step is 30-50 min;
the concentration of the ethanol in the fourth step is 50-65 ml/L.
According to the invention, the mass of the deionized water added in the sixth step is 1.5-3.2 times of the mass of the concentrated and dried mixed powder.
(III) advantageous effects
The invention has the beneficial effects that:
(1) the medicament has the advantages of obvious curative effect on neurasthenia and no toxic or side effect on a human body, wherein quetiapine can relieve the emotional symptoms such as depression, anxiety and cognitive deficit symptoms related to schizophrenia, and loxoprofen has the effects of resisting inflammation and relieving heat, and particularly has strong analgesic effect.
(2) The invention has the effects of clearing heat and reducing internal heat, nourishing kidney and tonifying liver, nourishing heart and soothing nerves, regulating vital energy and removing obstruction in channels and food retention, can effectively improve the functions of organisms and enhance the immunity, taurine has the effects of relaxing skeletal muscles and antagonizing myotonia, the metin has the effects of resisting inflammation, analgesia and fever, the trimetazidine can be used as a maintenance treatment medicine, can eliminate mental disorder, has the effects of clearing heat and removing dampness, and promoting qi and blood circulation, and has shorter treatment course and quicker effect.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1:
the invention provides a medicine for treating neurasthenia, which comprises the following components (in percentage by mass): trimetazidine: 2%, midecamycin: 5%, betamethadone: 30% and taurine: 17%, ketotifen: 2%, catechin: 25%, nicotinamide: 3%, oleanolic acid: 3%, quetiapine: 1.5%, loxoprofen: 11.5 percent.
Furthermore, the medicament for treating the neurasthenia is an oral preparation, and the oral preparation is a tablet; the dosage of the medicine for treating neurasthenia for adults is 2.6 mg/kg/day.
A preparation method of a medicine for treating neurasthenia in neurology comprises the following steps:
the method comprises the following steps: preparing materials: taking trimetazidine, midecamycin, theetarnerone, taurine, ketotifen, catechin, nicotinamide, oleanolic acid, quetiapine and loxoprofen according to the weight parts for later use respectively;
step two: drying and grinding into powder: putting trimetazidine, midecamycin, tea-leaf maiden, taurine, ketotifen, catechin, nicotinamide, oleanolic acid, quetiapine and loxoprofen into an oven for drying at 60-80 ℃, then carrying out a cooling process, and then putting into a dispensing tank for grinding into fine powder;
step three: and (3) crushing treatment: putting the prepared fine powder into an ultrafine pulverizer, and pulverizing into mixed powder consisting of micron-sized particles with volume average particle size of 0.3-12 microns and nano-sized particles with volume average particle size smaller than 0.3 microns for later use;
step four: preparing an ethanol solution: adding ethanol with the mass 2-4 times of that of the mixed powder, and stirring and dissolving to obtain an ethanol solution;
step five: concentrating and drying: standing the ethanol solution for 20-23 hours at 6-8 ℃, slowly percolating at the speed of 2-3 ml per minute by using a percolation method, collecting percolate, concentrating and drying for later use;
step six: extracting the medicine: and adding deionized water into the concentrated and dried mixed powder, stirring and dissolving uniformly, heating and concentrating to be pasty, standing for 0.6-0.9 hour, extracting and preparing into tablets to obtain the medicine for treating neurasthenia.
Example 2:
a medicine for treating neurasthenia comprises the following components (in percentage by mass): trimetazidine: 3%, midecamycin: 2%, dimenhydrinate: 35% and taurine: 16%, ketotifen: 4%, catechin: 24%, nicotinamide: 4%, oleanolic acid: 2%, quetiapine: 2%, loxoprofen: 8 percent.
Furthermore, the medicament for treating the neurasthenia is an oral preparation, and the oral preparation is a tablet; the dosage of the medicine for treating neurasthenia for adults is 2.7 mg/kg/day.
A preparation method of a medicine for treating neurasthenia comprises the following steps:
the method comprises the following steps: preparing materials: taking trimetazidine, midecamycin, theetarnerone, taurine, ketotifen, catechin, nicotinamide, oleanolic acid, quetiapine and loxoprofen according to the weight parts for later use respectively;
step two: drying and grinding into powder: putting trimetazidine, midecamycin, tea-leaf maiden, taurine, ketotifen, catechin, nicotinamide, oleanolic acid, quetiapine and loxoprofen into an oven for drying at 60-80 ℃, then carrying out a cooling process, and then putting into a dispensing tank for grinding into fine powder;
step three: and (3) crushing treatment: putting the prepared fine powder into an ultrafine pulverizer, and pulverizing into mixed powder consisting of micron-sized particles with volume average particle size of 0.3-12 microns and nano-sized particles with volume average particle size smaller than 0.3 microns for later use;
step four: preparing an ethanol solution: adding ethanol with the mass 2-4 times of that of the mixed powder, and stirring and dissolving to obtain an ethanol solution;
step five: concentrating and drying: standing the ethanol solution for 20-23 hours at 6-8 ℃, slowly percolating at the speed of 2-3 ml per minute by using a percolation method, collecting percolate, concentrating and drying for later use;
step six: extracting the medicine: and adding deionized water into the concentrated and dried mixed powder, stirring and dissolving uniformly, heating and concentrating to be pasty, standing for 0.6-0.9 hour, extracting and preparing into tablets to obtain the medicine for treating neurasthenia.
Example 3:
a medicine for treating neurasthenia comprises the following components (in percentage by mass): trimetazidine: 4%, midecamycin: 1%, theophyllimedone: 40% and taurine: 15%, ketotifen: 6%, catechin: 23%, nicotinamide: 5%, oleanolic acid: 1%, quetiapine: 2.5%, loxoprofen: 2.5 percent.
Furthermore, the medicament for treating the neurasthenia is an oral preparation, and the oral preparation is a tablet; the dosage of the medicine for treating neurasthenia for adults is 2.8 mg/kg/day.
A preparation method of a medicine for treating neurasthenia comprises the following steps:
the method comprises the following steps: preparing materials: taking trimetazidine, midecamycin, theetarnerone, taurine, ketotifen, catechin, nicotinamide, oleanolic acid, quetiapine and loxoprofen according to the weight parts for later use respectively;
step two: drying and grinding into powder: putting trimetazidine, midecamycin, tea-leaf maiden, taurine, ketotifen, catechin, nicotinamide, oleanolic acid, quetiapine and loxoprofen into an oven for drying at 60-80 ℃, then carrying out a cooling process, and then putting into a dispensing tank for grinding into fine powder;
step three: and (3) crushing treatment: putting the prepared fine powder into an ultrafine pulverizer, and pulverizing into mixed powder consisting of micron-sized particles with volume average particle size of 0.3-12 microns and nano-sized particles with volume average particle size smaller than 0.3 microns for later use;
step four: preparing an ethanol solution: adding ethanol with the mass 2-4 times of that of the mixed powder, and stirring and dissolving to obtain an ethanol solution;
step five: concentrating and drying: standing the ethanol solution for 20-23 hours at 6-8 ℃, slowly percolating at the speed of 2-3 ml per minute by using a percolation method, collecting percolate, concentrating and drying for later use;
step six: extracting the medicine: and adding deionized water into the concentrated and dried mixed powder, stirring and dissolving uniformly, heating and concentrating to be pasty, standing for 0.6-0.9 hour, extracting and preparing into tablets to obtain the medicine for treating neurasthenia.
The medicine for treating the neurasthenia can be prepared by the three groups of embodiments, wherein the medicine for treating the neurasthenia prepared by the second group of embodiments has the best effect, can effectively improve the body function and improve the immunity, has the advantages of obvious curative effect on the treatment of the neurasthenia and no toxic or side effect on a human body, and the quetiapine can relieve the emotional symptoms related to the schizophrenia, such as depression, anxiety and cognitive deficiency symptoms, has the effects of clearing heat and reducing internal heat, nourishing kidney and liver, nourishing heart and tranquilizing mind, regulating vital energy and dredging collaterals and removing food retention.
Clinical trial cases
Case 1: li A certain, female, age 48. Symptoms are: the patient feels emotional distress, excitability and fatigue easily in the early 2017, and has poor concentration. The oryzanol and the B vitamins are improved after being taken by a person. The above symptoms appeared again in 2017 in month 4. The patient can be diagnosed in 10 days after 4 months, and the patient can complain of dizziness, hypomnesis, insomnia, and aspermia. And (3) diagnosis: neurasthenia; after the combined medicament in the embodiment 1 developed by the applicant is tried out and the conventional auxiliary materials are added according to the conventional process to prepare the tablet, the mood is worried, the excitement and the fatigue are easy to occur, the attention is not concentrated, the memory decline is obviously improved, the tablet is continuously used for one month, the tablet can work like a normal person after being restored to be normal through examination, no adverse effect is shown, and the trial result obtains the favorable comment of a patient.
Case 2: in the norm, female, age 42. Symptoms are: insomnia, tiredness, hypodynamia, dizziness, palpitation, and other discomforts. And (3) diagnosis: neurasthenia; treatment: clearing heat, removing pathogenic fire, nourishing kidney and liver, nourishing heart, tranquilizing mind, regulating qi-flowing, and dredging collaterals; by trial of the combined medicament in the embodiment 2 developed by the applicant and adding conventional auxiliary materials according to a conventional process, the insomnia and dizziness of the patient are obviously relieved after 3 tablets each time, three times a day for one month. The patient feels palpitation and fatigue to be recovered to normal after continuously taking a treatment course, so the trial effect proves that the combined medicament of the embodiment of the invention is practical and effective.
Case 3: when a person is old, the person is male, 50 years old, 2016, 8, and 20 days old. Since the following 2 years, people have a head covering, palpitation, loss of interest in life and drowsiness, and the emotional depression is severe in the last month, the head CT photography in a certain hospital suggests that: no abnormality was found. Electroencephalogram: no obvious abnormality was observed. Depression scale assay: mild-moderate depression. After 2 months of trial, the above-mentioned alleviation is achieved, and after 1 month of continuous use, the symptoms completely disappear, and the spirit is refreshing. After 1 year follow-up, no recurrence was observed. Thus, the trial effect proves that the composition medicament of the embodiment is effective in treating depression caused by neurasthenia.
Case 4: first diagnosis of a certain disease, male, 42 years old, 7 months and 17 days in 2015. The main complaints are: insomnia, dizziness and restlessness at sitting and lying for 1 year. The medical history: before 1 year, insomnia, difficulty in falling asleep, easy waking after sleep, dizziness and discomfort feeling of restlessness of sitting and lying are caused by high working stress, and occasionally abdominal pain, abdominal distension and diarrhea are accompanied, and MRI + MRA examination is performed in 2016 for 1 month: no abnormality is seen, although the doctor is asked for and the medicine is taken in four places in recent years, the treatment of the Chinese medicine and the western medicine is not obviously relieved, and the diagnosis is made in 2016, 5, 13 days. And (3) diagnosis: neurasthenia; gastrointestinal neurosis. Treatment: after detailed examination, the patient is given the combination medicament in the example 1 developed by the applicant according to the actual situation of the patient, and the tablet prepared by adding conventional auxiliary materials is tried according to the conventional process and is treated three times a day. After trial for 3 months, the sleep is obviously improved, and other physical disorder symptoms are also relieved. After the trial treatment, the patient can work as normal people without adverse effects, and the trial result is favorable for the patient.
Case 5: certain Liu has a history of suffering from neurasthenia and cardiac neurosis for 5 years, a plurality of treatment methods such as oral administration and physical therapy have been performed before treatment, but all the treatment methods are not good, the disease condition is recurrent, and the disease condition is mild and severe, and then the combined medicament in the embodiment 2 developed by the applicant is tried and treated by adding conventional auxiliary materials into tablets according to the conventional process, and after 2 months of treatment, the symptoms completely disappear, and no adverse effect is shown, so the trial effect proves that the composition medicament of the embodiment is practical and effective in treating neurasthenia.
Case 6: li A certain woman, 53 years old, should be treated in 2016, 9 and 10 months. Dizziness, palpitation, drowsiness, insomnia and anxiety in the last 2 months since the following 1 year, which were suggested by MRI + MRA examination in a certain hospital: no abnormality was found. Electroencephalogram: no obvious abnormality was observed. The diagnosis is as follows: neurasthenia and anxiety disorder. The combined medicament in the embodiment 3 developed by the applicant is tried and treated by adding conventional auxiliary materials into tablets according to a conventional process, the symptoms are relieved after trial for 2 months, and the symptoms completely disappear after continuous use for 2 months, so that the spirit is bright. After 1 year follow-up, no recurrence was observed. Therefore, the trial results prove that the composition of the agent of example 3 is effective for treating anxiety disorder caused by neurasthenia.
Case 7: old certain, woman, age 48. Symptoms are: tiredness, hypodynamia, dizziness, poor memory, insomnia and other discomforts. And (3) diagnosis: neurasthenia; treatment: clearing heat, removing pathogenic fire, nourishing kidney and liver, nourishing heart, tranquilizing mind, regulating qi-flowing, and dredging collaterals; by trial of the combined medicament in the embodiment 2 developed by the applicant and adding conventional auxiliary materials according to a conventional process, the tablets are prepared for treating insomnia and dizziness of a patient for 2 months, three times a day and 3 tablets each time. After a treatment course, the patient's fatigue has been recovered to normal, so the trial effect proves that the combined medicament of the embodiment 2 of the invention is practical and effective.
It should be noted that: the above-mentioned embodiments are only used for illustrating the technical solution of the present invention, and not for limiting the same; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Claims (7)
1. A medicament for treating neurasthenia, which is characterized in that: the components by mass percent: trimetazidine: 2-4%, midecamycin: 1-5% of theophylline: 30-40% and taurine: 15-17% and ketotifen: 2-6% and catechin: 23-25% and nicotinamide: 3-5% of oleanolic acid: 1-3%, quetiapine: 1.5-2.5%, loxoprofen: 2.5-11.5%;
the medicine for treating neurasthenia is an oral dosage form, and the oral dosage form is a tablet;
the dosage of the medicament for treating neurasthenia for adults is 2.6-2.8 mg/kg/day;
the medicine has no toxic or side effect on human body.
2. The medicine for treating neurasthenia according to claim 1, wherein the components are as follows by mass percent:
trimetazidine: 2.5%, midecamycin: 4.5%, theometin: 31% and taurine: 16%, ketotifen: 2.5%, catechin: 24.5%, nicotinamide: 3.3% and oleanolic acid: 2.7%, quetiapine: 1.6%, loxoprofen: 11.4 percent.
3. The medicine for treating neurasthenia according to claim 1, wherein the components are as follows by mass percent:
trimetazidine: 3%, midecamycin: 2%, dimenhydrinate: 35% and taurine: 16%, ketotifen: 4%, catechin: 24%, nicotinamide: 4%, oleanolic acid: 2%, quetiapine: 2%, loxoprofen: 8 percent.
4. The medicine for treating neurasthenia according to claim 1, wherein the components are as follows by mass percent:
trimetazidine: 3.5%, midecamycin: 1.5%, and theimetone: 39.5%, taurine: 15.5%, ketotifen: 5%, catechin: 24%, nicotinamide: 4%, oleanolic acid: 2%, quetiapine: 2.3%, loxoprofen: 2.7 percent.
5. A method for preparing a medicament for treating neurasthenia according to any one of claims 1 to 4, which comprises the following steps:
the method comprises the following steps: preparing materials: taking trimetazidine, midecamycin, theetarnerone, taurine, ketotifen, catechin, nicotinamide, oleanolic acid, quetiapine and loxoprofen according to the weight parts for later use respectively;
step two: drying and grinding into powder: putting trimetazidine, midecamycin, tea-leaf maiden, taurine, ketotifen, catechin, nicotinamide, oleanolic acid, quetiapine and loxoprofen into an oven for drying at 60-80 ℃, then carrying out a cooling process, and then putting into a dispensing tank for grinding into fine powder;
step three: and (3) crushing treatment: putting the prepared fine powder into an ultrafine pulverizer, and pulverizing into mixed powder consisting of micron-sized particles with volume average particle size of 0.3-12 microns and nano-sized particles with volume average particle size smaller than 0.3 microns for later use;
step four: preparing an ethanol solution: adding ethanol with the mass 2-4 times of that of the mixed powder, and stirring and dissolving to obtain an ethanol solution;
step five: concentrating and drying: standing the ethanol solution at the temperature of 6-8 ℃ for 20-23 hours, slowly percolating at the speed of 2-3 ml per minute by a percolation method, collecting percolate, concentrating and drying for later use;
step six: extracting the medicine: and adding deionized water into the concentrated and dried mixed powder, stirring and dissolving uniformly, heating and concentrating to be pasty, standing for 0.6-0.9 hour, extracting and preparing into tablets to obtain the medicine for treating neurasthenia.
6. The method for preparing a medicament for treating neurasthenia according to claim 5, wherein the medicament comprises the following components in percentage by weight:
the crushing time in the third step is 30-50 min;
the concentration of the ethanol in the fourth step is 50-65 ml/L.
7. The method for preparing a medicament for treating neurasthenia according to claim 5, wherein the medicament comprises the following components in percentage by weight:
and in the sixth step, the mass of the deionized water added is 1.5-3.2 times of the mass of the concentrated and dried mixed powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910035030.9A CN109464451B (en) | 2019-01-15 | 2019-01-15 | Medicine for treating neurasthenia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910035030.9A CN109464451B (en) | 2019-01-15 | 2019-01-15 | Medicine for treating neurasthenia and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109464451A CN109464451A (en) | 2019-03-15 |
| CN109464451B true CN109464451B (en) | 2021-07-13 |
Family
ID=65678713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910035030.9A Active CN109464451B (en) | 2019-01-15 | 2019-01-15 | Medicine for treating neurasthenia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109464451B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7368097B2 (en) * | 2019-04-05 | 2023-10-24 | 第一三共ヘルスケア株式会社 | Oral pharmaceutical composition containing loxoprofen or its salt and taurine |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106177461A (en) * | 2016-08-22 | 2016-12-07 | 王海霞 | A kind of Chinese medicine and western medicine compound preparation treating neurasthenic syndrome and preparation method |
| CN108926554A (en) * | 2018-10-12 | 2018-12-04 | 中国科学院昆明植物研究所 | Application of the catechin in preparation treatment central nervous system disease drug |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| CN106668024A (en) * | 2016-12-27 | 2017-05-17 | 郑州郑先医药科技有限公司 | Western medicine composition for treating neurasthenia and application thereof |
| CN106668039A (en) * | 2016-12-27 | 2017-05-17 | 郑州郑先医药科技有限公司 | Drug composition for treating neurasthenia |
-
2019
- 2019-01-15 CN CN201910035030.9A patent/CN109464451B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106177461A (en) * | 2016-08-22 | 2016-12-07 | 王海霞 | A kind of Chinese medicine and western medicine compound preparation treating neurasthenic syndrome and preparation method |
| CN108926554A (en) * | 2018-10-12 | 2018-12-04 | 中国科学院昆明植物研究所 | Application of the catechin in preparation treatment central nervous system disease drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109464451A (en) | 2019-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102283999B (en) | Traditional Chinese medicine preparation for treating insomnia | |
| CN107126485B (en) | Traditional Chinese medicine composition for assisting in improving sleep and preparation method and application thereof | |
| CN103099866A (en) | Traditional Chinese medicine composition for treating anxiety and insomnia and preparation method thereof | |
| CN109464451B (en) | Medicine for treating neurasthenia and preparation method thereof | |
| CN112190638A (en) | Traditional Chinese medicine composition for treating insomnia after stroke in cerebral infarction recovery period and application thereof | |
| CN102125678B (en) | Chinese medicinal preparation for treating hysteria disease | |
| CN103341074A (en) | Application of Yixuanning granules in preparation of medicaments for treating insomnia | |
| CN112741890B (en) | Traditional Chinese medicine composition for treating vertigo and preparation method thereof | |
| CN102908396B (en) | Chinese medicinal composition for promoting sleeping and preparation method thereof | |
| CN113209218B (en) | Traditional Chinese medicine composition for treating ventricular premature beat of children and application thereof | |
| CN102552666A (en) | Chinese lavipeditum composition for treating insomnia | |
| CN113144084A (en) | Traditional Chinese medicine composition for treating frequent ventricular premature beat and application thereof | |
| CN111529659A (en) | Traditional Chinese medicine composition for treating bradyarrhythmia and preparation method and application thereof | |
| CN111166849A (en) | Medicated bath composition for removing fatigue and improving sleep | |
| CN112755144A (en) | Traditional Chinese medicine composition for preventing and treating jet lag and preparation method thereof | |
| CN104784495A (en) | Traditional Chinese medicine preparation for treating infantile convulsion and preparation method | |
| CN103961578A (en) | Traditional Chinese medicine medicinal liquor for treating neurasthenia | |
| CN103638461B (en) | Treatment anxiety neurosis's medicine pill | |
| CN115957265B (en) | Traditional Chinese medicine external treatment ointment for treating flaming up of deficiency fire and preparation method and application thereof | |
| US11771727B2 (en) | Traditional Chinese medicine composition and product for improving sleep by balancing yin and yang, method for making the same and use thereof | |
| CN115350260B (en) | Daily care biological agent with sleep-aiding function for skin and preparation method thereof | |
| CN112263656B (en) | Traditional Chinese medicine composition for treating AIDS-related sleep disorder and traditional Chinese medicine preparation thereof | |
| CN103585372B (en) | Traditional Chinese medicine preparation for treating cerebral palsy | |
| CN100571722C (en) | Treatment is suffered from a deficiency of the kidney and the pharmaceutical composition of climacteric syndrome and preparation method thereof | |
| CN106581362A (en) | Chinese patent medicine for treatment of neurasthenia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |